fecal microbiota spores, live-brpk · VOWST
Microbiome therapeutic
Evidence outlook
Approved: Recurrent Clostridioides Difficile Infection
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03183141 NCT03183141 · Recurrent Clostridioides Difficile Infection Run by former owner Seres Therapeutics This open-label, single-arm phase 3 study (ECOSPOR IV) gave SER-109 to 263 adults with recurrent Clostridioides difficile infection, without randomization, blinding or a control arm. Of these, 29 had rolled over from the earlier SERES-012 trial and 234 were newly enrolled. The primary endpoint was CDI recurrence up to week 8; sustained clinical response was recorded in 25 of 29 rollover participants and 215 of 234 newly enrolled participants, with no comparative analysis. Registry: NCT03183141 | 3 | Cohort 1: Recurrence of CDI and Sustained Clinical Response (Up to Week 8); Cohort 2: Recurrence of CDI and Sustained Clinical Response (Up to Weeks 8 and 12) 2022-04-29 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (1)
What this study did
Competitive landscape
This drug's own stage for Recurrent Clostridioides Difficile Infection: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Fecal Microbiota Spores, Live-Brpk (VOWST): this drug | Approved | Microbiome therapeutic | — | Weak signal | No reviewed efficacy summary in this indication | |
| AZD5148 | Phase 1(overall) | Monoclonal antibody | Clostridioides difficile toxin B (TcdB) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.